Genomic and Epigenomic Aberrations in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 31 December 2026 | Viewed by 2012
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer is driven by a complex interplay of genetic and epigenetic alterations that disrupt normal cellular processes. Genomic alterations, such as somatic mutations and copy number alterations, together with epigenomic alterations, such as DNA methylation and chromatin modifications, collectively shape tumor phenotypes. Deciphering the functional impact of these alterations and the underlying mechanisms is critical for developing precision medicine strategies and improving patient outcomes.
This Special Issue aims to provide a comprehensive platform for cutting-edge research and reviews on the role of genomic and epigenomic aberrations in cancer biology. We welcome contributions that explore the spectrum of alterations across cancer subtypes, their association with recurrence, and their functional implications in processes such as metastasis, immune evasion, and metabolic rewiring.
Submissions may include, but are not limited to the following: (1) (Epi)genomic Alterations and Cancer Subtypes: Genomic and epigenomic signatures linked to tumor classification, initiation, progression, recurrence, tumor evolution models and drug response; (2) Functional (Epi)genomics: Mechanistic insights into how alterations shape various tumor phenotypes, such as metastasis, immune escape, and metabolic reprogramming; (3) Molecular Mechanisms: Molecular pathways and regulatory potentials connecting genomic and epigenomic changes to oncogenesis and therapy resistance.
Dr. Xiaofan Ding
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- genomic mutation
- epigenetic alteration
- functional genomics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
